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Abstract Until now, the anatomic extent of tumor (TNM
classification) has been by far the most important factor to
predict the prognosis of colorectal cancer patients. However,
in recent years, data collected from large cohorts of human
cancers demonstrated that the immune contexture of the
primary tumors is an essential prognostic factor for patients’
disease-freeandoverallsurvival.Tumoralandimmunological
markers predicted by systems biology methods are involved
in the shaping of an efficient immune reaction and can serve
as targets for novel therapeutic approaches. Global analysis of
tumor microenvironment showed that the nature, the func-
tional orientation, the density, and the location of adaptive
immune cells within distinct tumor regions influence the risk
of relapse events. The density and the immune cell location
withinthetumorhaveaprognosticvaluethatissuperiortothe
TNM classification, and tumor invasion is statistically
dependent on the host-immune reaction. Thus, the strength
of the immune reaction could advance our understanding of
cancer evolution and have important consequences in clinical
practice.
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1 Estimating the outcome in cancer: the major role
of the host’s immune system
The outcome prediction in cancer is usually achieved by
evaluating tissue samples obtained during surgical removal
of the primary tumor, mostly focusing on their histological
characteristics. These include the extent of the tumor within
the tissue, atypical cell morphology, tissue integrity,
aberrant expression of protein markers or malignant
transformation, senescence and proliferation, various char-
acteristics of the invasive margin, depth of invasion, and the
extent of vascularization. In addition, histological or
radiological analysis of both tumor draining and regional
lymph nodes, as well as of distant organs, can be carried
out looking for evidence of metastases. Based on these
data, the evaluation of cancer progression is performed and
is further serving to estimate patient prognosis. Available
statistical data of patients with similar progression charac-
teristics and their actual outcome parameters such as
average disease-free (DFS), disease-specific (DSS), and
overall survival (OS) are used for estimation. Until now,
tumor staging (AJCC/UICC-TNM classification) summa-
rizes data on tumor burden (T), presence of cancer cells in
draining and regional lymph nodes (N), and evidence for
metastases (M). With the large amount of statistical data
available on cancer patients’ survival with a given progres-
sion stage, such approaches have been shown to be
valuable in estimating the outcome in cancer [1–3].
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significantly vary between patients within the same histo-
logical tumor stage. The progression of advanced stage
cancer can remain stable for years, and partial or full
regression of large metastatic lesions can also occur
spontaneously. For example, considering only the chest
metastatic tumors, 76 reports have demonstrated spontane-
ous regression [4]. The most common primary tumors were
renal cell carcinoma and also hepatocellular carcinoma,
endometrial stromal sarcoma, pleomorphic liposarcoma,
and esophageal cancer. Similarly, spontaneous regression
of metastases from melanoma and spontaneous remissions
in colorectal cancer metastases were shown [5, 6].
On the other hand, the rapid relapse and death of patients
with an early cancer was reported even after an apparently
complete surgical removal of the tumor, with undetectable
levels of residual tumor burden and without signs of
metastasis. One reason for the apparently limited accuracy
of the traditional staging in predicting the outcome of the
patients could be the usual estimation of the tumor
progression as a largely autonomous process, focusing only
on cancer cells and without considering the evolution of the
cancer as a balance of factors which can enhance or
suppress the tumor [7].
Recently, many reports supporting the hypothesis that
cancer development is strictly controlled by the host’s
immune system were published. This underlines the
importance of the systemic and local immunological
biomarkers that even at the level of clinically apparent
tumors should be evaluated in predicting the outcome [7,
8]. Moreover, such markers were shown to be superior to
the conventional histologic criteria in estimating DFS, DSS,
and OS [9–11].
2 Mechanisms of metastasis
Metastasis is mainly the dissemination of the tumor cells
from the primary site and their colonization in distant
organs. It is a complex process and has many different
steps. In order to metastasize, tumor cells detach from the
primary tumor and invade the surrounding tissue. They
migrate through the stroma, intravasate into vessels, and the
majority ends up traveling through the portal vein system.
During transportation, they manage to survive mechanical
stresses and escape from the immune system. In colorectal
cancer, tumor cells adhere to endothelial cells of the liver,
contact the extracellular matrix, and extravasate into the
tissue. In the liver parenchyma, tumor cells establish a
crosstalk with the stroma, and like this, a special microen-
vironment is created. In a tumor-favorable microenviron-
ment, signals of proliferation and neoangiogenesis will lead
to macroscopic liver metastasis formation [12–14]. Even
though liver metastasis accounts for the vast majority of
cancer deaths of colorectal cancer (CRC) patients, funda-
mental questions about its molecular and cellular mecha-
nisms still remain unanswered.
The availability of DNA array technologies, allowing
genome-wide analyses, has been providing new insights on
the cancer development and metastasis. Expression profiling
studies in CRC have mainly focused on comparisons of
normal mucosa, adenoma, and primary carcinomas. Few
studies have thrown light on the differences or similarities
between primary tumors and metastases. For this reason,
many molecular alterations involved in the CRC adenoma to
carcinoma transition are characterized and, comparatively,
littleisknownonthe possiblemechanismsofmetastases[15].
In order to determine metastatic signatures by microarray
technology in CRC, three different strategies have been
followed, as reported in 12 different studies [16–27]. The
first approach consists of comparing transcriptional profiles
of primary CRC from metastasis-free patients to those from
patients affected by metastatic spread. This information is
combined with the survival of those patients within a 5-year
follow-up period, with the goal of finding gene expression
profiles as prognostic markers of metastatic spread. The
second strategy is to compare the gene expression in primary
tumors with their matched metastases. The third approach
comprises comparisons of expression profiles from CRC cell
lines with different metastatic potential. The gene expression
studies support the notion that primary tumors genetically
resemble their matched metastases more than primary
counterpart from other patients [27]. Even if metastatic gene
expression profiles have been proposed in the aforemen-
tioned studies, unfortunately, those do not show much in
common. Gene expression patterns do not overlap enough to
show consistency. Only few genes reported in at least two
independent studies have been linked to metastatic ability. It
is interesting that no expression profile has been specifically
linked to liver metastases in CRC.
Apart fromthe geneexpressionprofiling,other techniques,
such as genomic profiling, have also been used to determine
metastatic ability in CRC. Genomic analyses of primaries and
their matched metastases [28] showed that CRC primary
tumors have a similar genomic pattern with their
corresponding metastases. Array-based comparative ge-
nomic hybridization was used to detect genetic alterations
in CRC that predict survival after liver resection [29].
Genome-wide copy number analyses revealed the involve-
ment of cyclin D3 in liver metastasis formation in CRC [30].
However, a significant amount of experimental data from
individual gene proposes that tumor cells have a metastatic
signature [31, 32]. In fact, there is considerable genetic
heterogeneity among primary and metastatic tumors.
Recently, massive parallel paired-end sequencing was
performed in pancreatic cancer metastases to identify
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evaluate clonal relationships among primary and metastatic
cancers [33, 34]. Data indicate that the majority of
somatically acquired mutations occur before the develop-
ment of metastatic lesions. Analyses of multiple primary
tumor pieces and metastatic lesions revealed a clonal
evolution within the primary tumors, with distinct and
large subclones that give rise to various metastases. This
mix of geographically distinct subclones, each containing
large numbers (hundreds of millions) of cells, is present
within the primary tumor years before the metastases
become clinically evident. The features of these
metastasis-promoting subclones have yet to be discerned
since no consistent genetic signature could be identified.
However, the mutations were not metastasis-specific per se
as they were present in the matched primary carcinoma of
the same patients, and there is no evidence that the
mutations observed endowed these genes with metastagenic
activity. Thus, there is considerable genetic heterogeneity
among cells capable of initiating metastasis. The selective
pressure within the primary carcinoma that led to the
formation of progressor mutations is still to be revealed
[34]. Such selective pressure could be immune-related.
3 Immunosurveillance despite inflammation
It has been well documented that developing tumors are
exposed to and usually eliminated by an intact immune
system. The innate and adaptive immune systems can
protect the host against tumor development through
mechanisms of immunosurveillance [35, 36]. A series of
publications demonstrated, in mouse models, that immune
deficiencies were associated with the growth and aggres-
siveness of tumors, and the immunoediting concept was
proposed [35, 37]. These data put in a new light previous
clinical observations of higher cancer incidence in immu-
nodepressed individuals [38]. The growth of established
tumors can be effectively suppressed and hold back over
large periods of time (immunological equilibrium). At the
molecular level, cancer progression is strongly influenced
by this immunological pressure (cancer immunoediting)
[35, 39]. In humans the equilibrium process was mainly
inferred from clinical observations [40]. Tumor masses
developed from tumor cells escaping this control can be
rejected by the host’s immune system upon proper re-
stimulation [41, 42]. It was also shown that the adaptive
immune system of a naive mouse has the ability to destroy
tumor cells and to sculpture tumor immunogenicity, but
also can restrain the growth of cancer for extended periods
of time [43].
Histopathological analyses of colorectal cancers show
that many tumors are infiltrated by inflammatory and
lymphocytic cells, in variable quantities [44, 45]. A closer
look reveals that the latter are not distributed randomly, but
seem to be organized in more or less dense infiltrations in
the center of the tumoral zone (CT), in boarding edges at
the invasive margin (IM) of tumoral nests, and in lymphoid
islets adjacent to the tumor.
4 A general scheme of the immune control of human
tumors
In a study conducted on several hundreds of colorectal cancer
samples with well-documented histological and molecular
data, it was demonstrated that the absence of histological
markers of ongoing metastatic invasion (vascular emboli,
lymphatic invasion, and perineural invasion, collectively
termed as VELIPI) closely associated with both longer DFS
and OS and with the infiltration of the tumor with CD3
+ T
cells, CD3
+CD4
+ Th e l p e r ,a n dC D 3
+CD8
+ cytotoxic T cells
[46]. Expression of genes involved in cytotoxic antitumor
responses, such as granzyme B (GZMB) and granulysin
(GLNY), genes of Th1-differentiation, e.g., the transcription
factors T-box protein 21 (T-BET) and interferon regulatory
factor 1 (IRF-1) and the characteristic Th1 cytokine
interferon gamma (IFNG) were increased in non-relapsing
patients VELIPI-negative compared to VELIPI-positive
relapsing patients. Striking differences between VELIPI-
positive and VELIPI-negative tumors were shown for the
CD45RO
+ memory T cell density, including its two
compartments, early (CD45RO
+CCR7
−CD28
+CD27
+)a n d
effector (CD45RO
+CCR7
−CD28
−CD27
−)m e m o r y .T h i s
suggests that properly stimulated memory T cells are
involved in the suppression of CRC progression and, in
general, are associated with a favorable outcome [46]. Those
results were extended with the finding that Th1 response-
related genes (CD3-z, CD8b, GZMB, GLNY, T-BET, IRF-1,
and IFNG) create in fact an extremely tightly regulated
cluster [9], and their expression is inversely correlated with
the probability of relapse. Although the frequency of
immune cells staining positive for these markers is some-
times highly variable in CTand IM, the assessment of CD3
+,
CD8
+,G Z M B
+, and CD45RO
+ cell density by immunos-
taining could be confirmed at the protein level too. The
combined CD3 and CD45RO staining of colorectal cancer
tumors was very convincingly shown to predict the outcome
of the patients in a more reliable way than conventional
TNM histopathology-based evaluation [9]. These results
demonstrated that a proper spatial organization and a high
density of effector T cells associated with an optimal gene
expression-level activation and correlated with a good
prognosis in patients with colorectal cancer.
Interestingly, similar conclusions can be made by
comparing colorectal cancer patient cohorts categorized by
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presence or absence of metastases (META+ and META−,
respectively) [47]. Although there are no striking differ-
ences in the composition of the infiltrate of Lo META− and
Lo META+ patients, however, brisk infiltration of the
primary tumor, along with increased density of CD3
+CD8
+
cytotoxic T cells, NKT cells, and tumor-associated macro-
phages, is associated with absence of metastases (typical for
the Hi META− patient group). Conversely, decreased
frequency of cells involved in cellular immune responses
and a shift toward B cell infiltration was typical for patients
developing metastasis in spite of immune infiltration (Hi
META+ group). Furthermore, the massive immune infil-
trate predicting the absence of metastases suggested the
presence of a well-represented late-stage memory Tcell arm
(CD45RA
−CD27
−), while the early phase of memory T cell
differentiation showed no major difference between Hi
META− and Hi META+ patients. Correlation analysis of
various T cell markers suggested that mainly CD8
+
cytotoxic T cells and the memory cell development are
compromised in Hi META+ patients. Not surprisingly, in
Hi META− patients, markers of early T cell activation
(CD45RA
+CD27
+/CD25
+/CD28
+/CD69
+) showed strong
correlation with macrophage and DC migration markers,
while in Hi META+ patients, all those clusters of co-
expression were dramatically disrupted [47].
Taken together, these data suggest that sufficient immune
infiltration with successful priming and differentiation of
CD8 T cells is vital for a successful suppression of
metastasis development. In case of a weak immune cell
infiltration (Lo), however, all the aforementioned correla-
tions were completely absent regardless of the presence or
absence of metastases (Lo META+ vs. Lo META−). This
suggests that either the immune suppression and the escape
can be locally initiated before the actual metastatic spread
and/or factors other than the immune activation are also
involved in the suppression of CRC metastasis develop-
ment. Finally, the apparent inefficiency of the immune
infiltrate in reaching a critical level of organization and
significantly influencing the metastatic spread in Lo META
+ and Lo META− patients can also indicate that a certain
level of immune infiltration is a prerequisite for a successful
antitumor immune response.
The impact of an organized immune response was also
measured on the primary tumor mass by using Ki67 as a
marker of proliferation and M30 as a marker of apoptosis.
The primary tumor mass was shown to be largely resistant
to immune-mediated attacks, in striking contrast with the
apparent vulnerability of developing metastases that are
determining the disease outcome. Interestingly, the mRNA
level of cytotoxic response markers, such as co-expression
of GLNYand IRF-1, predicted more than nine times longer
DFS than DFS observed in their absence [47]. In the same
time, many classic tumor markers of apoptotic resistance,
cancer spread, vascularization, and general progression, e.g.
survivin, carcinoembryonic antigen-related cell adhesion
molecule 1 (CEACAM1), CD97, angiotensin-converting
enzyme, estrogen receptor-binding fragment-associated
gene 9, matrix metallopeptidase 7, and vascular endothelial
growth factor (VEGF), had a little impact on the clinical
disease outcome [48]. Markers of the TH2 commitment, e.
g., gata binding protein 3 (GATA3) and immunosuppres-
sion, such as interleukin 10 (IL-10) and forkhead box P3
(FoxP3) were not found to be important for DFS [48]. Still,
high levels of EGFR expression predisposed patients to a
short DFS [48], and although VEGF did not have a
significant impact on DFS when analyzed in all colorectal
cancer patients, it decreased the DFS in patients with an
otherwise favorable GLNY
+IRF-1
+ infiltrate, suggesting
the enhanced capillary formation as an escape option from
immune-mediated destruction of early metastases [47].
An obvious question that has both mechanistic and
potential therapeutic importance is what shapes an efficient
immune reaction. Genes significantly associated with
colorectal cancer patient survival were used to predict
new functionally related markers. The experimental and the
in silico data were integrated in a gene–gene network that
included the hazard ratio information and a structured
description of the corresponding biological functions. The
functional pattern of the predicted genes was assessed using
ClueGO, a Gene Ontology-based tool as functionally
grouped networks [49]. Among the major biological roles
identified by this novel visualization tool were leukocyte
activation, positive regulation of signal transduction, regu-
lation of programmed cell death, positive regulation of cell
proliferation, positive regulation of cell migration, and
chemotaxis. In fact, the highest prediction score concerned
the chemokine genes CX3CL1, CXCL9, and CXCL10.
Indeed, when experimentally tested, high expression of
these genes in the tumors correlated with high densities of
Th1/cytotoxic memory T cells and with favorable progno-
sis. It therefore appears that certain chemokines are
involved in building an efficient immune contexture at the
tumor site, whereas others, such as CXCL5 for instance, do
not [48].
An adaptive immune response is characterized by
antigen recognition and repertoire selection. However,
numerous studies failed to identify a restricted T cell
repertoire in human tumors. In colorectal cancer, the
immunoscope analysis of the T cells purified from excised
tumors revealed a highly polyclonal repertoire. In a
correlation matrix, the VB families and CDR lengths
clustered with the expression of CX3CL1, CXCL9, and
CXCL10. Subfamilies of TCRs from this cluster correlated
with clinical outcome, whereas TCR subfamilies from the
bulk of T cells did not [48]. These data, although still far
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the tumor, suggest that appropriate chemokines attract T
cell subpopulations, some of them being concentrated after
recognition of, and stimulation by, antigens which may be
relevant targets for immune control of cancers.
5 Predictors of favorable outcome
In addition to enlighten some aspects of host–tumor
interactions, the analysis of the immune reaction may also
provide novel useful prognostic markers. As in all solid
tumors, the CRC prognosis is currently defined by the
TNM staging which integrates tumor size, lymph node, and
metastatic invasion [1–3]. This staging is crucial, particu-
larly for patients with no detectable lymph node invasion
(stage II) who are usually treated by surgery alone.
However, 20–30% of these patients will relapse and may
have beneficiated from adjuvant chemotherapy. We, thus,
performed a study to determine whether the immune pattern
may help discriminate between relapsing and non-relapsing
patients. Based on analyses of immune infiltrate coordina-
tion, an immune score (Im) reflecting the CD8/CD45RO
density in CT and IM was defined [50]. Tumors with low
CD8 and CD45RO in CT and IM were classified Im0,
patients with high infiltrate of one marker in one zone were
classified Im1 and then Im2, and Im3 up to Im4 for tumors
with high infiltrate of CD8 and CD45RO cells in both CT
and IM. The analysis of 599 early-stage (stage I and II)
colorectal cancers revealed a highly significant correlation
between disease-free and overall survival and the immune
scoring. Patients with a low immune score (Im0 and Im1)
were of very bad prognosis, while patients with a high
immune score (Im3 and Im4) experienced a very low level
of recurrence. The immune scoring was significant over
TNM staging, providing a precise prognosis of the
recurrence and may therefore encourage to treat patients
with low immune score with adjuvant therapies [50].
We showed that a Th1 polarization with cytotoxic and
memory T cells in the center and the invasive margin of the
tumor was shown to be the major factor influencing the
clinical outcome. Previous studies focusing on the host
response in CRC indicated a possible positive prognostic role
for the presence of lymphoid infiltrates [51]. To our
knowledge, the prognostic value we observed is far beyond
that mentioned in previous reports of immune markers in
CRC and other solid tumors. To explain this difference, we
demonstrated that the combination of immune parameters
associating the nature, the density, the functional orientation,
and the distribution of immune cells within the tumor would
all be essential to accurately define the impact of the local
host immune reaction in CRC. We have previously proposed
to define these immune criteria as “immune contexture” [10].
6 Memory T cell responses and survival in human
cancer: remember to stay alive
Our results suggest that once human CRCs become
clinically detectable, the adaptive immune response plays
a role in preventing tumor recurrence. Despite immunoedit-
ing mechanisms, the beneficial effect of the adaptive
immunity may persist throughout tumor progression (stages
II and III) [9, 11]. Intratumoral T cells could modify tumor
stroma or tumor cells in ways that attenuate the metastatic
potential of tumor cells. The absence of microscopic
evidence of early metastatic invasiveness within lympho-
vascular vessels was strongly positively correlated with
high densities of intratumoral effector memory T cells. An
appealing interpretation of these data is that even when a
tumor has already reached a clinical stage, efficient
adaptive immune reaction can keep tumor emboli in check.
Since cancers present the physiopathological characteristics
of chronic and evolutive diseases, it is not surprising to
observe differentiated memory T cells within tumors. It
could be hypothesized that effector memory T cells may be
directly involved in the control of cancer progression. The
cytotoxic and cytokinic capability of effector memory T
cells may provide them the relevant weapons to control
tumor progression and metastatic invasion at the primary
tumor site. On the other hand, the observation of high
intratumoral immune reaction in patients with advanced
metastatic cancer could indicate that the immune system is
unable to efficiently prevent metastatic dissemination.
Thus, other antitumoral immune mechanisms may be
implicated in a reduced relapse occurrence.
Because the primary tumor is removed by surgery, the
prognostic value associated with the host response in
colorectal cancer may reflect the quality of systemic effectors
for recognition and killing of circulating cancer cells in
peripheral blood, peritoneal cavity, bone marrow, or lymph
nodes. The effector memory T cell’sa b i l i t yt o“remember”
previously encountered antigens leads to faster response on
reexposure.Followingaprimaryresponsetoantigen,memory
T cells disseminate and are maintained in the body for long
periods [52]. As suggested in mice [53], the trafficking
properties and the long-lasting antitumor capacity of
memory T cells could result in long-term immunity in
human CRC.
It is suspected that the metastatic invasion can lead to the
dissemination of tumoral foci that can remain in an
asymptomatic and non-detectable state of dormancy (i.e.,
not expanding in mass) for long periods of time before
cancer reemergence [54–56]. The control of cancer dor-
mancy involves various mechanisms like cellular dormancy
(G0-G1 arrest), angiogenic dormancy, and immunosurveil-
lance [57]. Indeed, stable lesions of transformed immuno-
genic cells in mice were controlled by the host’s adaptive
Cancer Metastasis Rev (2011) 30:5–12 9immune system in a condition of “equilibrium” [43]. In
these experiments, loss of either immunocompetence or
immunogenicity could lead to tumor outgrowth. Based on
these data, it could be hypothesized that human cancer
relapse may arise either because of the loss of the protective
antitumoral immunity and/or the “awakening” of dormant
tumors. This could explain why occult cancer can be
transplanted from an organ of a donor—apparently cured
from cancer—to a recipient [40] who is at the same time
naive to the transplanted tumor cell antigens and under
immunosuppressant treatment. In this context, our data
suggest that depending on the strength and localization of
the antitumoral immune response elicited in situ, distinct
quantity (number of clones) and quality (differentiation state)
of memory T cells could be generated among the patients.
7 Lessons from human cancer analysis
In contrast to the infiltration with cells responsible for
chronic inflammation, the presence of high numbers of
lymphocytes, especially T cells, has also been reported as
being of good prognosis in many cancer types: melanoma,
non-Hodgkin’s lymphoma, non-small cell lung cancer,
breast, ovarian, head, neck, esophagus, urothelial, and
colorectal cancer [35, 46, 58–65]. The impact of immune
responses and tumor escape on metastasis and on patient
prognosis still remains poorly understood. We investigate in
situ immune responses in human colorectal cancer accord-
ing to metastatic lymph node or distant organ invasion [47].
Non-metastatic patients presented significant correlations
between cytotoxic and effector memory T subpopulations.
These correlation profiles were absent in tumors with low T
cell infiltrates and were altered in metastatic patients with
high T cell infiltrates. Overall investigation of the primary
tumor microenvironment allowed us to uncover four major
intratumoral immune profiles within primary tumors
depending on the balance between tumor escape and
immune coordination: (1) strong and coordinated cytotoxic
Th1 immune responses (GNLY/IRF1) without or (2) with
tumor angiogenesis (VEGF), (3) non-coordinate immune
responses and (4) weak (Lo) immune reactions (immune
ignorance?). These distinct immune profiles are associated
with significant distinct cancer outcome (relapse risk) [47].
Particularly elaborated in colorectal cancer, the impact of
the immune contexture has been demonstrated in many
other human tumors and appears to be a general phenom-
enon [8]. It is interesting to note that it concerns not only
various organs (breast, colon, lung, head and neck, kidney,
bladder, ovary, prostate, etc.) but also various cancer cell
types (adenocarcinoma, squamous cell carcinoma, large cell
cancer, melanoma, etc.). It concerns tumors considered as
immunogenic, such as melanoma or renal cell cancer, in
which the success of active IL2, IFN, or TIL immunotherapy
had been documented [66], as well as tumors in which there
is, so far, no success of these approaches, which leaves open
the search for alternative novel immunotherapies.
8 Concluding remarks: from tumor-immune infiltrates
to tumor-immune contexture
Lymphocytic infiltration is a common feature of human
cancers, including those who develop in immunoprivileged
sites, such as the eye [67]. Our data demonstrate that the
immune contexture strongly influences the clinical out-
come. High density of memory T cells with Th1 and
cytotoxic orientation appears to be the strongest predictor
of tumor recurrence following surgery. It is thus tempting to
postulate that effector memory T cells prevent the escape of
potentially metastatic cells from the primary tumor, dimin-
ishing the risk of relapse after tumor removal.
A still open question is whether T cell infiltration is a
prognostic factor or predicts response to chemotherapy, as
suggested by a previous study [68]. The analysis of the
nature, the quantity, the location, and the functionality of
the immune infiltrates in human cancers becomes an
essential measure in establishing the prognosis of a human
cancer. The molecular and immunohistochemical technolo-
gies which should allow the spreading of such analysis in
routine laboratories are currently being refined.
Considering the probable universal character of the
immune control of tumors, it is essential to stop ignoring
it as a prognostic factor [8] and to introduce the immune
score as a marker to classify cancers [11, 50]. This marker
has a dual advantage: Firstly, it appears to be the strongest
prognostic factor for disease-free and overall survival
particularly in early-stage cancers; secondly, it provides a
tool or a target for novel therapeutic approaches.
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